Early extensive viremia, but not rs8099917 genotype, is the only predictor for cholestatic hepatitis C after living-donor liver transplantation

2012 ◽  
Vol 43 (6) ◽  
pp. 621-629 ◽  
Author(s):  
Toru Ikegami ◽  
Ken Shirabe ◽  
Takasuke Fukuhara ◽  
Norihiro Furusyo ◽  
Kazuhiro Kotoh ◽  
...  
Keyword(s):  
Liver Transplantation ◽  
Hepatitis C ◽  
Living Donor ◽  
Living Donor Liver Transplantation ◽  
Cholestatic Hepatitis ◽  
Donor Liver ◽  
Donor Liver Transplantation

scholarly journals PNPLA3 as a liver steatosis risk factor following living-donor liver transplantation for hepatitis C

2017 ◽  
Vol 48 (3) ◽  
pp. E335-E339 ◽  
Author(s):  
Hisamitsu Miyaaki ◽  
Satoshi Miuma ◽  
Naota Taura ◽  
Hidetaka Shibata ◽  
Akihiko Soyama ◽  
...  
Keyword(s):  
Liver Transplantation ◽  
Risk Factor ◽  
Hepatitis C ◽  
Living Donor ◽  
Living Donor Liver Transplantation ◽  
Liver Steatosis ◽  
Donor Liver ◽  
Donor Liver Transplantation

scholarly journals Living-Donor Liver Transplantation and Hepatitis C

HPB Surgery ◽  
2013 ◽  
Vol 2013 ◽  
pp. 1-13 ◽  
Author(s):  
Nobuhisa Akamatsu ◽  
Yasuhiko Sugawara
Keyword(s):  
Liver Transplantation ◽  
Hepatitis C ◽  
Living Donor ◽  
Living Donor Liver Transplantation ◽  
Antiviral Treatment ◽  
Sustained Viral Response ◽  
Deceased Donor ◽  
Donor Liver ◽  
Donor Liver Transplantation ◽  
Primary Indication

Hepatitis-C-virus- (HCV-) related end-stage cirrhosis is the primary indication for liver transplantation in many countries. Unfortunately, however, HCV is not eliminated by transplantation and graft reinfection is universal, resulting in fibrosis, cirrhosis, and finally graft decompression. In areas with low deceased-donor organ availability like Japan, living-donor liver transplantation (LDLT) is similarly indicated for HCV cirrhosis as deceased-donor liver transplantation (DDLT) in Western countries and accepted as an established treatment for HCV-cirrhosis, and the results are equivalent to those of DDLT. To prevent graft failure due to recurrent hepatitis C, antiviral treatment with pegylated-interferon and ribavirin is currently considered the most promising regimen with a sustained viral response rate of around 30% to 35%, although the survival benefit of this regimen remains to be investigated. In contrast to DDLT, many Japanese LDLT centers have reported modified treatment regimens as best efforts to secure first graft, such as aggressive preemptive antiviral treatment, escalation of dosages, and elongation of treatment duration.

Sign in / Sign up

Export Citation Format

Share Document